Gilead Sciences has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient. Read More
from Canoe https://ift.tt/3g9Hfps
Black Mag Would you like to share your story, your advice or your lessons in life with over 3 million monthly readers of blackmag.tk?
No comments:
Post a Comment